Last checked at (Sharecast News) - Point-of-care business EKF Diagnostics said on Monday that it looked set to trade ahead of market expectations for the full year.
EKF cited strong trading in October, combined with expected orders for the remainder of the year, for driving its 2020 performance ahead of market expectations, which had already been revised upwards several times during the year.
The AIM-listed firm now expects to deliver group revenues and adjusted underlying earnings "comfortably ahead" of market consensus of £60.0m and £23.0m, respectively.
EKF said the performance was driven by "significantly improved" trading in the group's core business in the final quarter, along with continued orders for its PrimeStore MTM Covid-19 sample collection device.
As of 1015 GMT, EKF shares were up 1.61% at 78.75p.
29 Apr 2020 10:59
EKF Diagnostics to supply collection device for Covid-19 testing
(Sharecast News) - Point-of-care business EKF Diagnostics Holdings has signed an agreement with Source BioScience to supply a novel patented sample collection device for its growing Covid-19 testing service.
Read more